A Comparative Study of the Effects of Al(OH) 3 and AlPO 4 Adjuvants on the Production of Neutralizing Antibodies (NAbs) against Bovine parainfluenza Virus Type 3 (BPIV3) in Guinea Pigs.

Autor: Heidary R; Department of Microbiology and immunology, Faculty of Veterinary Medicine, University of Tehran, Tehran, Iran., Nikbakht Brujeni G; Department of Microbiology and immunology, Faculty of Veterinary Medicine, University of Tehran, Tehran, Iran., Lotfi M; Razi Vaccine and Serum Research Institute, Agricultural Research, Education and Extension Organization (AREEO), Karaj, Iran., Hajizadeh A; Razi Vaccine and Serum Research Institute, Agricultural Research, Education and Extension Organization (AREEO), Karaj, Iran., Yousefi AR; Razi Vaccine and Serum Research Institute, Agricultural Research, Education and Extension Organization (AREEO), Karaj, Iran.
Jazyk: angličtina
Zdroj: Archives of Razi Institute [Arch Razi Inst] 2023 Dec 30; Vol. 78 (6), pp. 1779-1786. Date of Electronic Publication: 2023 Dec 30 (Print Publication: 2023).
DOI: 10.32592/ARI.2023.78.6.1779
Abstrakt: Aluminum-containing adjuvants are extensively used in inactive human and animal vaccines owing to their favorable immunostimulatory and safe properties. Nonetheless, there is controversy over the effects of different aluminum salts as an adjuvant for the bovine parainfluenza virus type 3 (BPIV3) vaccine. In order to find a suitable adjuvant, we studied the effects of two adjuvants (i.e., aluminum hydroxide [Al(OH) 3 ] and aluminum potassium sulfate [AlPO 4 ]) on the production of neutralizing antibodies (NAbs) for an experimental BPIV3 vaccine. The animals under study (Guinea pigs) were randomly assigned to five groups of experimental vaccines containing Al(OH) 3 (AH), AlPO 4 (AP), Al(OH) 3 -AlPO 4 mixture (MIX), commercial vaccine (COM), and control (NS). The treatment groups were immunized with two doses of vaccine 21 days apart (on days 0 and 21), and the control group received normal saline under the same conditions. The animals were monitored for 42 days, and blood samples were then taken. The results indicated that all vaccines were able to induce the production of NAbs at levels higher than the minimum protective titer (0.6). An increase in titer was observed throughout the monitoring period. Moreover, an increase in both the level and mean titer of NAbs obtained from the vaccine containing Al(OH) 3 adjuvant was significantly higher than in the other studied groups (P≤0.005). The comparison of NAbs titer in other groups did not display a significant difference. Considering the speed of rising and the optimal titer of NAbs production in the experimental vaccine, the Al(OH) 3 adjuvant is a suitable candidate for preparing a vaccine against BPIV3 for immunization.
Competing Interests: The authors declare that they have no conflict of interest.
Databáze: MEDLINE
Externí odkaz: